Eli Lilly’s (NYSE:LLY) recent 50% price cut for the two lowest doses of its weight loss drug Zepbound for self-paying customers has coincided with increased costs for some patients using the ...

Novo Nordisk has unveiled a new direct-to-patient online pharmacy which will offer Wegovy at less than half its standard price.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

The maker of the weight loss drug Zepbound is offering the drug at a reduced price for people willing to buy it directly from the company in vials, rather than auto-injector pens.

Eli Lilly will now sell cheaper vials of Zepbound, presenting a direct challenge to telehealth companies that offer compounded versions of the medication.

Eli Lilly (NYSE:LLY) shares edged around 0.7% lower Tuesday as the company announced a price cut for its obesity drug Zepbound.

Drugmaker Eli Lilly is significantly lowering the prices of the two lowest doses of its blockbuster weight loss drug Zepbound.

In February, Eli Lilly cut the monthly price for lower-dosage vials of its obesity drug Zepbound by $50 for consumers who pay cash via the drugmaker's LillyDirect website.

Cigna now offers employers $200 Wegovy, Zepbound copay option The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Eli Lilly (LLY) cuts prices for weight loss drug Zepbound for self-paying customers but raises costs for patients in the assistance program. Read more here.

Eli Lilly (NYSE:LLY) shares edged around 0.7% lower Tuesday as the company announced a price cut for its obesity drug Zepbound. The new single-dose vials, available in 2.5 mg and 5 mg doses, are ...